 WATERTOWN, Mass., Nov. 04, 2021 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation TPD to deliver novel small molecule protein degrader medicines, today announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancers SITC 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually, and at the 63rd American Society of Hematology ASH Annual Meeting, taking place from December 11 14, 2021 in Atlanta, GA and virtually. 